Biohaven Stock Drops 5.3% Amid Market Volatility

Shares of the biopharmaceutical company fall as analysts weigh in on the stock's performance.

Apr. 6, 2026 at 6:35pm

Got story updates? Submit your updates here. ›

An extreme close-up of intricate, industrial-looking financial machinery and equipment, conveying the heavy, physical nature of the banking and investment systems that underpin the stock market.Biohaven's stock decline reflects broader volatility in the financial markets, as investors closely watch the company's progress on its pipeline of neurological treatments.New Haven Today

Shares of Biohaven Ltd. (NYSE:BHVN) dropped 5.3% during trading on Monday, closing at $9.29. The stock traded as low as $9.34, with trading volume declining 81% from the average daily volume. The drop comes as analysts have provided mixed ratings and price targets for the company.

Why it matters

Biohaven is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and neurovascular diseases. The company's stock performance is closely watched by investors as it navigates the drug development and regulatory approval process.

The details

Several research analysts have weighed in on Biohaven's stock. HC Wainwright reduced their price target from $11 to $10 and maintained a 'neutral' rating. The Goldman Sachs Group upgraded the stock to a 'strong-buy' rating, while Citigroup boosted its price target from $14 to $17 and maintained a 'buy' rating. Overall, the stock has a 'Moderate Buy' consensus rating among analysts.

  • Biohaven's stock closed at $9.80 on the previous trading day.
  • The stock traded as low as $9.34 on Monday.

The players

Biohaven Ltd.

A clinical-stage biopharmaceutical company focused on developing therapies for neurological and neurovascular diseases.

HC Wainwright

A research firm that reduced its price target on Biohaven's stock.

The Goldman Sachs Group

A research firm that upgraded Biohaven's stock to a 'strong-buy' rating.

Citigroup

A research firm that boosted its price target on Biohaven's stock.

Got photos? Submit your photos here. ›

What they’re saying

“HC Wainwright reduced their price target on shares of Biohaven from $11.00 to $10.00 and set a 'neutral' rating for the company.”

— HC Wainwright, Research Firm

“The Goldman Sachs Group raised shares of Biohaven to a 'strong-buy' rating.”

— The Goldman Sachs Group, Research Firm

“Citigroup boosted their target price on shares of Biohaven from $14.00 to $17.00 and gave the company a 'buy' rating.”

— Citigroup, Research Firm

What’s next

Investors will continue to monitor Biohaven's stock performance and any updates from the company on its drug development pipeline and regulatory approvals.

The takeaway

Biohaven's stock volatility reflects the inherent risks and uncertainties in the biopharmaceutical industry, as the company navigates the complex drug development and approval process. Analysts have provided mixed views on the stock, highlighting the need for investors to closely follow the company's progress.